Skip to main content
The Markets by Proactive
Go to Proactive Australia

Archive

Cardiol Therapeutics sees positives for company after GW Pharma and Jazz Pharma announcement

Cardiol Therapeutics sees positives for company after GW Pharma  and Jazz Pharma announcement

Cardiol Therapeutics (TSE: CRDL- OTCQX: CRTPF) CEO David Elsley joined Steve Darling to offer his perspective on Jazz Pharmaceuticals acquiring GW Pharma for 7.2 billion dollars. Elsley talks about what that means for the CBD Pharma industry and what it could potentially mean for Cardiol Therapeutics.